Abintus Bio is pursuing in vivo CART products that directly reprogram immune cells from within their native environment using a proprietary viral platform technology. Leveraging $275M in prior technology advancement, the founding team has the relevant playbook and 75 years of collective in vivo virus know how from discovery to pre-launch.
